Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2007 1
2009 1
2010 1
2012 2
2013 4
2014 3
2015 3
2016 14
2017 6
2018 6
2019 13
2020 11
2021 11
2022 4
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society. Herrlinger U, et al. Among authors: kebir s. Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14. Lancet. 2019. PMID: 30782343 Free article. Clinical Trial.
A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma.
Kebir S, Ullrich V, Berger P, Dobersalske C, Langer S, Rauschenbach L, Trageser D, Till A, Lorbeer FK, Wieland A, Wilhelm-Buchstab T, Ahmad A, Fröhlich H, Cima I, Prasad S, Matschke J, Jendrossek V, Remke M, Grüner BM, Roesch A, Siveke JT, Herold-Mende C, Blau T, Keyvani K, van Landeghem FKH, Pietsch T, Felsberg J, Reifenberger G, Weller M, Sure U, Brüstle O, Simon M, Glas M, Scheffler B. Kebir S, et al. Clin Cancer Res. 2023 Jan 17;29(2):488-500. doi: 10.1158/1078-0432.CCR-22-0611. Clin Cancer Res. 2023. PMID: 36239995 Free PMC article.
KDM5B predicts temozolomide-resistant subclones in glioblastoma.
Ullrich V, Ertmer S, Baginska A, Dorsch M, Gull HH, Cima I, Berger P, Dobersalske C, Langer S, Meyer L, Dujardin P, Kebir S, Glas M, Blau T, Keyvani K, Rauschenbach L, Sure U, Roesch A, Grüner BM, Scheffler B. Ullrich V, et al. Among authors: kebir s. iScience. 2023 Dec 3;27(1):108596. doi: 10.1016/j.isci.2023.108596. eCollection 2024 Jan 19. iScience. 2023. PMID: 38174322 Free PMC article.
Are we providing best-available care to newly diagnosed glioblastoma patients? Systematic review of phase III trials in newly diagnosed glioblastoma 2005-2022.
Oster C, Schmidt T, Agkatsev S, Lazaridis L, Kleinschnitz C, Sure U, Scheffler B, Kebir S, Glas M. Oster C, et al. Among authors: kebir s. Neurooncol Adv. 2023 Sep 4;5(1):vdad105. doi: 10.1093/noajnl/vdad105. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37811538 Free PMC article. Review.
How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis.
Jabbarli R, Ahmadipour Y, Rauschenbach L, Santos AN, Darkwah Oppong M, Pierscianek D, Quesada CM, Kebir S, Dammann P, Guberina N, Scheffler B, Kaier K, Stuschke M, Sure U, Wrede KH. Jabbarli R, et al. Among authors: kebir s. Cancers (Basel). 2021 Jul 27;13(15):3770. doi: 10.3390/cancers13153770. Cancers (Basel). 2021. PMID: 34359673 Free PMC article.
Regorafenib in patients with recurrent high-grade astrocytoma.
Kebir S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK, Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K, Kleinschnitz C, Scheffler B, Glas M. Kebir S, et al. J Cancer Res Clin Oncol. 2019 Apr;145(4):1037-1042. doi: 10.1007/s00432-019-02868-5. Epub 2019 Feb 28. J Cancer Res Clin Oncol. 2019. PMID: 30820715
Vemurafenib for leptomeningeal melanomatosis.
Schäfer N, Scheffler B, Stuplich M, Schaub C, Kebir S, Rehkämper C, Mack F, Niehusmann P, Simon M, Greschus S, Kuchelmeister K, Herrlinger U, Glas M. Schäfer N, et al. Among authors: kebir s. J Clin Oncol. 2013 Apr 10;31(11):e173-4. doi: 10.1200/JCO.2012.46.5773. Epub 2013 Mar 4. J Clin Oncol. 2013. PMID: 23460716 No abstract available.
11C-MET PET/MRI for detection of recurrent glioma.
Deuschl C, Kirchner J, Poeppel TD, Schaarschmidt B, Kebir S, El Hindy N, Hense J, Quick HH, Glas M, Herrmann K, Umutlu L, Moenninghoff C, Radbruch A, Forsting M, Schlamann M. Deuschl C, et al. Among authors: kebir s. Eur J Nucl Med Mol Imaging. 2018 Apr;45(4):593-601. doi: 10.1007/s00259-017-3916-9. Epub 2017 Dec 28. Eur J Nucl Med Mol Imaging. 2018. PMID: 29282517
Feasibility and tolerability of trofosfamide and etoposide in progressive glioblastoma.
Schmidt T, Agkatsev S, Feldheim J, Oster C, Blau T, Sure U, Keyvani K, Kleinschnitz C, Stuschke M, Herrmann K, Deuschl C, Scheffler B, Kebir S, Glas M, Lazaridis L. Schmidt T, et al. Among authors: kebir s. Neurooncol Adv. 2023 Jul 20;5(1):vdad090. doi: 10.1093/noajnl/vdad090. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 37547266 Free PMC article.
77 results